Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (GB:0A4W)
LSE:0A4W
RESEARCH TOOLSreports
ACADIA Pharmaceuticals (0A4W) Share Price & Analysis
0 Followers
0A4W Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$16.60 - $33.96
Previous Close$17.09
Volume1.86K
Average Volume (3M)1.46K
Market Cap
$2.78B
Enterprise Value$2.46B
Total Cash (Recent Filing)$366.69M
Total Debt (Recent Filing)$48.10M
Price to Earnings (P/E)N/A
Beta-0.05
Next Earnings
May 01, 2024EPS Estimate
$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding164,771,521
10 Day Avg. Volume158
30 Day Avg. Volume1,459
Standard Deviation0.13
R-Squared0.15
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.60
Price to Sales (P/S)14.92
Price to Cash Flow (P/CF)8.20
P/FCF Ratio8.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit4.86
Enterprise Value/Ebitda-17.77
Forecast
1Y Price Target
$30.23Price Target Upside76.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
ACADIA Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAdvancement of a novel 'next-gen' pimavanserin candidate, ACP-204, with de-risked development and upcoming clinical trials.
Market ExpansionPotential for market expansion of Daybue outside the US, pending further market analysis and regulatory insights.
Product LaunchThe ongoing Daybue launch is seen as the main catalyst for the stock.
Bears Say
Clinical Trial OutcomesDisappointing ADVANCE-2 trial results for Nuplazid in negative symptoms of schizophrenia led to removing sales forecasts.
Price Target AdjustmentReduction of price target to $25 from $39 after failure of the ADVANCE-2 trial.
Stock ValuationDowngrade of ACAD stock to Neutral due to the absence of near-term major catalysts.
---
Options Prices
Currently, No data available
---
Ownership Overview
51.75% Insiders
19.20% Mutual Funds
16.37% Other Institutional Investors
12.67% Public Companies and
Individual Investors
0A4W FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest share price was $16.60 and its highest was $33.96 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
Currently, no data Available
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is May 01, 2024 which is in 12 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Feb 27, 2024. The company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.289 by -$0.009.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is $0.06.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 164,771,510 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.28 in its last earnings report, missing expectations of $0.289. Following the earnings report the stock price went down -9.758%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 1B.
---
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.23 (76.89% Upside)
$30.23 (76.89% Upside)
Blogger Sentiment
Bullish
GB:0A4W Sentiment 83%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.05%
12-Months-Change
Fundamentals
Return on Equity
-14.73%
Trailing 12-Months
Asset Growth
27.41%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
0A4W Company Deck
---
0A4W Earnings Call
Q4 2024
0:00 / 0:00
---
0A4W Stock 12 Months Forecast
Average Price Target
$30.23
▲(76.89% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Esperion
―
Ionis Pharmaceuticals
―
Best Analysts Covering 0A4W
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+8.08%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +8.08% per trade.
---